https://scholars.lib.ntu.edu.tw/handle/123456789/444391
標題: | New facets of antifungal therapy | 作者: | Chang Y.-L. Yu S.-J. Heitman J. Wellington M. YING-LIEN CHEN |
關鍵字: | combination therapy; fungal pathogens; new antifungal formulations | 公開日期: | 2017 | 卷: | 8 | 期: | 2 | 起(迄)頁: | 222-236 | 來源出版物: | Virulence | 摘要: | Invasive fungal infections remain a major cause of morbidity and mortality in immunocompromised patients, and such infections are a substantial burden to healthcare systems around the world. However, the clinically available armamentarium for invasive fungal diseases is limited to 3 main classes (i.e., polyenes, triazoles, and echinocandins), and each has defined limitations related to spectrum of activity, development of resistance, and toxicity. Further, current antifungal therapies are hampered by limited clinical efficacy, high rates of toxicity, and significant variability in pharmacokinetic properties. New antifungal agents, new formulations, and novel combination regimens may improve the care of patients in the future by providing improved strategies to combat challenges associated with currently available antifungal agents. Likewise, therapeutic drug monitoring may be helpful, but its present use remains controversial due to the lack of available data. This article discusses new facets of antifungal therapy with a focus on new antifungal formulations and the synergistic effects between drugs used in combination therapy. ? 2017 Taylor & Francis. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/444391 | ISSN: | 21505594 | DOI: | 10.1080/21505594.2016.1257457 | SDG/關鍵字: | amphotericin B; amphotericin B deoxycholate; amphotericin B lipid complex; anidulafungin; antifungal agent; caspofungin; fluconazole; flucytosine; isavuconazole; isavuconazonium; itraconazole; ketoconazole; micafungin; posaconazole; scy 078; unclassified drug; voriconazole; vt 1161; antifungal agent; echinocandin; polyene; triazole derivative; antifungal resistance; antifungal therapy; aspergillosis; candidiasis; coccidioidomycosis; combination chemotherapy; cryptococcosis; drug efficacy; drug monitoring; drug potentiation; drug safety; fungicidal activity; human; iatrogenic disease; immunocompromised patient; meta analysis (topic); mycosis; nonhuman; pharmacokinetic assay; phase 1 clinical trial (topic); phase 2 clinical trial (topic); prophylaxis; randomized controlled trial (topic); Review; systemic mycosis; Zygomycetes; chemistry; combination drug therapy; drug development; Invasive Fungal Infections; microbiology; Mycoses; Antifungal Agents; Drug Discovery; Drug Synergism; Drug Therapy, Combination; Echinocandins; Humans; Immunocompromised Host; Invasive Fungal Infections; Mycoses; Polyenes; Triazoles |
顯示於: | 植物病理與微生物學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。